Equity
€239,662 ▼ 12.9%
MEDSYS paid out €123,491 in dividends. That is 140% of the 2025 profit.
MEDSYS
Lifetime
20 annual accounts with figures on one time axis, 32 filings since 1994peak €406,459 (2018)
€170,272▼ 7.0%
lowest -€872,768 (2007)
€87,987▲ 107%
peak €526,696 (2006)
€239,662▼ 12.9%
€164,007▲ 198%
peak 8.6 FTE (2009)
-not published
Board4 names since 2017
2 directorsTanguy Bertrand and 1 other
Owners5 names in the annual accounts
100%GUALIMA
Documentsfilings and deeds
29-05-202663 days before the deadline
2025micro format
Result from €42,535 to €87,987Dividend €123,491Equity from €275,166 to €239,662Debts from €55,055 to €164,007Cash from €86,132 to €153,557
Key points
from the 2025 annual accountsTurnover
≈ €430,000 estimated
The micro format states no turnover.
Staff
1 FTE from 8.6 in 2009
Between 2009 and 2025, 88% of the full-time equivalents disappeared.
Liquidity
2.46 was 6.00 in 2024
Short-term debts rose from €55,055 to €164,007.
Filings
32 annual accounts since 1994
Five of the last ten came late. The 2019 accounts came latest: 90 days after the end of the period.
Position in the sector
€87,987
Higher net result than 91% of companies in other manufacturing. Sector median €7,577 · 786 companies.
Checked score
95
Excellent
Financially stronger than 62% of micro companies in other manufacturing (NACE 32)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.3% across 1,141 companies (NACE 32, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.2%
01-2025: 0.2%● unchanged vs 12-2024
02-2025: 0.2%● unchanged vs 01-2025
03-2025: 0.2%● unchanged vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025
08-2025: 0.3%▲ +0.1 percentage points vs 07-2025highest value
09-2025: < 0.1%▼ -0.3 percentage points vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026lowest value
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
lowers risk
Liquidity: current ratio 2.46, cash €153,557
Founded in 1993
Equity €239,662 (59.4% of total assets)
Size: total assets €403,669
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 32, micro). It does better than 66% of them on solvency, 77% on liquidity, 81% on profitability and 26% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 31,368 companies had the same profile as MEDSYS has now. Each dot stands for 79 companies, two years later.
93.5%
were still trading
5.9%
stopped another way
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of MEDSYS itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,368 companies, not a prediction for MEDSYS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €22,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 2.46 (6.0 in 2024), above the usual 1.5. Short-term debt is 40.6% and cash 38% of total assets. 40.6% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-05-2026, 63 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
63 days early
2024
27 days late
2023
26 days late
2022
4 days early
2021
74 days late
2020
55 days late
2019
90 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 29 days after the deadline. In the sector (NACE 32), the median for financial year 2024 was 2 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 27 August (4 of the last 5 accounts filed within 47 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0450817990
2 directors appointed, 2 resignations
Resignations: Olivier ROUVEZ (managing director) and Fabienne ARNOULD · Appointments: TRANDIUM (director) and Tanguy Bertrand (director) · Permanent representative: Marie Bertrand · General meeting of 04-09-2024 · Gazette deed
Reappointments: Olivier ROUVEZ (director) and Fabienne ARNOULD (director)
General meeting of 13-12-2023 · Gazette deed
Reappointments: Olivier ROUVEZ (managing director) and Fabienne ARNOULD (director)
General meeting of 26-06-2023 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MEDSYS Gembloux | €403,669 | €170,272 | 59.4% | - |
| ORTHOPEDIE LANCKMANS Roosdaal | €448,842 | €173,878 | 75.5% | - |
| Orthopedie BRANTS Geel | €376,970 | €146,712 | 75.3% | - |
| Ambachtelijke Orthopedische Schoentechniek Halen | €353,674 | €213,283 | 65.7% | - |
| DENTISCERAM Zaventem | €324,967 | €210,697 | 86.8% | - |
| NOVADENT Boom | €379,500 | €165,044 | 81.8% | - |
| LEXEL Asse | €414,136 | €243,825 | 84.6% | 1.6 |
These companies have the same main activity as MEDSYS: manufacture of medical and dental instruments and supplies (NACE 32500). They are comparable in size and age: total assets between €325,000 and €449,000, founded between 1985 and 1998.
Official details
Source: KBO- Status
- Active since 07-09-1993Normal situation
- Activity
- Manufacture of medical and dental instruments and suppliesNACE 32500
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 2025
- Establishment unit
- 2.063.512.9695030 Gembloux, since 16-09-1993
- Financial year end
- 31 December
- Peppol
- Reachable since 19-12-2025
Annual accounts 2025
- €403,669▲ 22.2%
- Employeeson 31-12-2025
- 1
- Filing
- Filed on 29-05-2026, 63 days before the end of the filing period
Insights on MEDSYS
MEDSYS files the micro format. That format states no turnover. The gross margin rose from -€115,920 in 2006 to €170,272 in 2025.
GUALIMA holds all the shares. In September 2024, the Official Gazette published the appointment of Trandium as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MEDSYS
- What is the company number of MEDSYS?
- The company number of MEDSYS is 0450.817.990. The VAT number is the same number with BE in front: BE 0450.817.990.
- Where is MEDSYS based?
- The registered office is at Rue du Gaillard,Sauv. 3, 5030 Gembloux.Company details
- What does MEDSYS do?
- According to the KBO register, the main activity is manufacture of medical and dental instruments and supplies (NACE 32500).
- What is the legal form of MEDSYS?
- MEDSYS is a public limited company (NV).
- When was MEDSYS founded?
- MEDSYS was founded on 07-09-1993.
- Is MEDSYS still active?
- Yes, MEDSYS is an active enterprise in the KBO register.
- How many employees does MEDSYS have?
- MEDSYS had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does MEDSYS fall under?
- In its 2025 annual accounts, MEDSYS states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of MEDSYS?
- The turnover in financial year 2025 is ≈ €430,000. This figure is estimated from the gross margin of €170,272 and 2,203 comparable companies of the same size. It probably lies between €280,000 and €660,000. It is a rough estimate.
- Is MEDSYS profitable?
- In financial year 2025, MEDSYS made a profit of €87,987.
- Where can I find the annual accounts of MEDSYS?
- MEDSYS filed 32 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MEDSYS due?
- MEDSYS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.